Kura Oncology (NASDAQ:KURA) Insider Francis Burrows Sells 1,311 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Francis Burrows sold 1,311 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $11,091.06. Following the completion of the sale, the insider owned 32,424 shares in the company, valued at $274,307.04. This represents a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Francis Burrows also recently made the following trade(s):

• On Thursday, December 18th, Francis Burrows sold 23,726 shares of Kura Oncology stock. The shares were sold at an average price of $9.78, for a total value of $232,040.28.

Kura Oncology Stock Performance

Shares of KURA stock traded down $0.10 on Tuesday, reaching $8.47. The stock had a trading volume of 1,149,028 shares, compared to its average volume of 1,287,347. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $12.49. The stock has a market cap of $737.06 million, a P/E ratio of -3.42 and a beta of 0.25. The company has a 50 day simple moving average of $10.33 and a 200 day simple moving average of $9.05.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in KURA. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Kura Oncology by 41.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,363 shares of the company’s stock worth $482,000 after acquiring an additional 13,579 shares during the period. Merit Financial Group LLC lifted its holdings in Kura Oncology by 124.0% in the 4th quarter. Merit Financial Group LLC now owns 22,499 shares of the company’s stock worth $234,000 after purchasing an additional 12,454 shares in the last quarter. Xcel Wealth Management LLC grew its holdings in Kura Oncology by 16.2% during the 4th quarter. Xcel Wealth Management LLC now owns 118,846 shares of the company’s stock valued at $1,235,000 after buying an additional 16,525 shares in the last quarter. CWM LLC raised its position in shares of Kura Oncology by 32.3% during the fourth quarter. CWM LLC now owns 156,544 shares of the company’s stock valued at $1,626,000 after buying an additional 38,181 shares during the last quarter. Finally, Flower City Capital lifted its holdings in shares of Kura Oncology by 20.0% in the fourth quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after buying an additional 2,000 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on KURA shares. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Tuesday, January 13th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Wedbush reissued an “outperform” rating and set a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Zacks Research downgraded Kura Oncology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 20th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.